multiple myeloma

Black patients with multiple myeloma waited an average of four months longer than White patients for a hematopoietic stem cell transplant,  according to a study of 495 patients treated by the Moffitt Cancer Center inf Florida. The transplant is an infusion of healthy stem cells after chemotherapy to reestablish the blood cell production process in …

Black patients with multiple myeloma wait longer than White patients for transplants Read More »

Black patients were significantly underrepresented in pivotal clinical trials supporting FDA approvals of CAR T-cell therapies for patients with blood cancers, especially multiple myeloma. Chimeric antigen receptor–T cell (CAR-T) therapy, a major advancement in the treatment of blood cancers, is currently approved for use in multiple myeloma. Its use is reserved for advanced, relapsed, or …

Black patients underrepresented in clinical trials of CAR-T drug treatment for blood cancers Read More »

Black people with multiple myeloma live longer than white patients with similar disease symptoms when both receive the same new and updated medical treatments, according to an analysis of more than 24,000 patients treated between 1999 and 2017. However, Black myeloma patients were less likely to receive the latest treatments than White patients, even if they had …

Blacks live longer than Whites with multiple myeloma if they get equal treatment Read More »

Although African-American men are three times more likely to be diagnosed with multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study led by researchers at the Keck School of Medicine of USC. That is problematic considering that African-Americans — the most at-risk population for …

Most research on multiple myeloma based on people of European descent even though Black men are 3 times more likely to have disease Read More »